Pulmonary artery catheterization, also called Swan-Ganz catheterization, is the procedure which involves insertion of catheter into the right side of the heart and to the arteries that lead to the lungs. It is used in the diagnosis of problems such as to determine the hemodynamic abnormalities in heart and lungs. This catheter allows measurement of pressure in pulmonary artery, right ventricle, and wedge pressure of left atrium.
The procedure of pulmonary artery catheterization can be used to evaluate risk of heart attack, shock, heart failure, pulmonary edema, cardiomyopathy, pulmonary hypertension and often used to check the complications in the kidneys. The catheters can be used with an IV-through which heart medications can be delivered and the effects of the medications can be monitored and checked by pulmonary artery catheter. Pulmonary artery catheters or Swan-Ganz catheters can be used in combination with an endocardial biopsy and it also helps to determine if medication is needed to lower the blood pressure, as pulmonary heart pressure should be low for heart transplant patients.
Increasing incidence of heart and lung diseases driving the pulmonary catheter market
According to WHO report in 2015, cardiovascular diseases were responsible for 31% of all global death. Rising incipience of cardiovascular diseases creates a highly conducive environment for growth of the pulmonary artery catheter market. Also, high prevalence of diabetes, hypertension, owing to change in lifestyle of people, and smoking and drinking habits further supplements market growth.
The growing number of geriatric population in the world driving the pulmonary artery catheter market. However, there are some restraints in the use of pulmonary artery catheter such as it is not recommended for patients with acute respiratory distress syndrome, septic shocks, and in the routine treatment for patients undergoing high risk of surgery. The most hazardous risk of using pulmonary artery catheter is pulmonary artery rupture and risk to the patients receiving anticoagulation therapy.
Increase in number of cardiac clinics globally expected to boost growth of pulmonary artery catheter market
The global pulmonary catheter market can be segmented by product type, end user, application, and region
On the basis of product type,
On the basis of application,
On the basis of end user,
The rising number of patients with heart and lung complications owing to increase in use of pulmonary artery catheter in North America
Regional segmentation of pulmonary artery catheter market by Coherent Market Insights comprises North America, Asia Pacific, Europe, Africa, and Middle East. North America region dominates the pulmonary artery catheters market, mainly due to high prevalence of cardiovascular disorder as a result of sedentary lifestyle. The changing lifestyle, unhealthy diet, the increase in people with habits such as smoking and drinking, increase in stress level owing to increase in population of patients which leads to the growth of pulmonary artery catheters market. Followed by North America, Europe and Asia Pacific are also one of the emerging market for pulmonary artery catheter. The change in lifestyle, lack of exercise in people, and increasing geriatric population in this region are some the factors driving growth of the pulmonary artery catheter market in this region.
Rapid use of pulmonary artery catheter by physicians is expected to aid pulmonary artery catheter market growth
Key players operating the pulmonary catheter market globally include ICU Medical, argon Medical, Edwards Life Sciences Corporation, Biosensors International and Becton Dickinson (BD). The rapid use of pulmonary artery catheters by physicians in the treatment of heart and lung disorders is expected to drive the pulmonary artery catheters market.